tildrakizumab

FDA Drug Profile

Drug Details

Generic Name
tildrakizumab
Brand Names
N/A
Application Number
Sponsor
SAMSUNG BIOLOGICS Co., Ltd.
NDC Codes
1
Dosage Forms
LIQUID
Routes
N/A
Active Ingredients
TILDRAKIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE ILUMYA ® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1 )